Discovering and identifying optimal use of adjuvants - from Sep 9th
Information
Watch on demand on Sep 24, or join LIVE on Sep 9 by registering here:
www.attendee.gotowebinar.com/register/65990897655842318
Workshop leader opening remarks
Dr Wolfgang Leitner, Chief, Innate Immunity Section, Basic Immunology Branch, NIAID, NIH
AS03 adjuvant for COVID-19 vaccine development
Dr Derek O'Hagan, Senior Advisor in R&D, GSK Vaccines
Precision adjuvants: Developing adjuvantation systems tailored to target populations
Dr Ofer Levy, Director, Precision Vaccines Program, Boston Children’s Hospital & Professor, Harvard Medical School
Impacts of Formulation and Delivery on Vaccine Safety and Immunogenicity
Dr Jay Evans, President and CEO, Inimmune Corporation & Director, Center for Translational Medicine, University of Montana
Identification of immune signatures of novel adjuvant formulations using machine learning
Dr Elke S. Bergmann-Leitner, Malaria Vaccine Branch, US Military Malaria Research Program, Walter Reed Army Institute of Research
Programming Multifaceted and Durable Pulmonary T Cell Immunity using combination adjuvants
Dr M. Suresh, John E. Butler Professor of Comparative and Mucosal Immunology, University of Wisconsin-Madison
Perspectives of vaccine adjuvant discovery and development, and funding opportunities for adjuvant research
Dr Wolfgang Leitner, Chief, Innate Immunity Section, Basic Immunology Branch, NIAID, NIH
Next Generation Saponin Adjuvants for Improved Vaccines
Dr Tyler Martin, MD, Chairman, President & CEO, Adjuvance Technologies, Inc.
Panel with all speakers
